62P KI67 in ER+HER2-negative pure invasive lobular breast carcinoma (ILC). What’s the best Ki67 threshold to differentiate prognosis?

M Bellet-Ezquerra,P Gomez Pardo,R Fasani,G Villacampa,M Portu,G Serna,L Joval,A Petit,A Fernandez Ortega,J Jimenez,E Zamora,M.J Gil,L Sanz Gomez,C Viaplana,F Gallego,V Peg Cámara,C Saura Manich,S Pernas Simon,P.G Nuciforo

doi:10.1016/j.esmoop.2023.101286

62P KI67 in ER+HER2-negative pure invasive lobular breast carcinoma (ILC). What’s the best Ki67 threshold to differentiate prognosis?

M Bellet-Ezquerra, P Gomez Pardo + Show 17 more

Open Access

https://doi.org/10.1016/j.esmoop.2023.101286

Copy DOI

Journal: ESMO Open	Publication Date: May 1, 2023
License type: cc-by-nc-nd

Affiliation: Vall d'Hebron Institute of Oncology, Solti, Duran i Reynals Hospital, Vall d'Hebron Institut de Recerca, Bellvitge University Hospital, Vall d'Hebron Hospital Universitari, Institut Català d'Oncologia

#Invasive Lobular Breast Carcinoma #Pure Invasive Lobular Carcinoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

62P KI67 in ER+HER2-negative pure invasive lobular breast carcinoma (ILC). What’s the best Ki67 threshold to differentiate prognosis?

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: ESMO Open

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.